Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT019580...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/ https://www.ncbi.nlm.nih.gov/pubmed/29654415 http://dx.doi.org/10.1007/s10549-018-4769-z |
_version_ | 1783335698220187648 |
---|---|
author | Verma, Sunil O’Shaughnessy, Joyce Burris, Howard A. Campone, Mario Alba, Emilio Chandiwana, David Dalal, Anand A. Sutradhar, Santosh Monaco, Mauricio Janni, Wolfgang |
author_facet | Verma, Sunil O’Shaughnessy, Joyce Burris, Howard A. Campone, Mario Alba, Emilio Chandiwana, David Dalal, Anand A. Sutradhar, Santosh Monaco, Mauricio Janni, Wolfgang |
author_sort | Verma, Sunil |
collection | PubMed |
description | PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. PROs were assessed using the European Organisation for Research and Treatment of Cancer core quality-of-life (EORTC QLQ-C30) and breast cancer-specific (EORTC QLQ-BR23) questionnaires. Changes from baseline and time to deterioration in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively. Exploratory analysis of area-under-the-curve for change from baseline in pain score (AUC-pain) was performed. RESULTS: On-treatment HRQoL scores were consistently maintained from baseline and were similar between arms. A clinically meaningful (> 5 points) reduction in pain score was observed as early as Week 8 and was maintained up to Cycle 15 in the ribociclib arm. A statistically significant increase in mean AUC-pain was also observed in the ribociclib arm. Scores for all other EORTC QLQ-C30 and EORTC QLQ-BR23 domains were maintained from baseline and were similar between arms. CONCLUSIONS: HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2− advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population. |
format | Online Article Text |
id | pubmed-6022531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-60225312018-07-06 Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 Verma, Sunil O’Shaughnessy, Joyce Burris, Howard A. Campone, Mario Alba, Emilio Chandiwana, David Dalal, Anand A. Sutradhar, Santosh Monaco, Mauricio Janni, Wolfgang Breast Cancer Res Treat Clinical Trial PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. PROs were assessed using the European Organisation for Research and Treatment of Cancer core quality-of-life (EORTC QLQ-C30) and breast cancer-specific (EORTC QLQ-BR23) questionnaires. Changes from baseline and time to deterioration in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively. Exploratory analysis of area-under-the-curve for change from baseline in pain score (AUC-pain) was performed. RESULTS: On-treatment HRQoL scores were consistently maintained from baseline and were similar between arms. A clinically meaningful (> 5 points) reduction in pain score was observed as early as Week 8 and was maintained up to Cycle 15 in the ribociclib arm. A statistically significant increase in mean AUC-pain was also observed in the ribociclib arm. Scores for all other EORTC QLQ-C30 and EORTC QLQ-BR23 domains were maintained from baseline and were similar between arms. CONCLUSIONS: HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2− advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population. Springer US 2018-04-13 2018 /pmc/articles/PMC6022531/ /pubmed/29654415 http://dx.doi.org/10.1007/s10549-018-4769-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Verma, Sunil O’Shaughnessy, Joyce Burris, Howard A. Campone, Mario Alba, Emilio Chandiwana, David Dalal, Anand A. Sutradhar, Santosh Monaco, Mauricio Janni, Wolfgang Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title_full | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title_fullStr | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title_full_unstemmed | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title_short | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 |
title_sort | health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from monaleesa-2 |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/ https://www.ncbi.nlm.nih.gov/pubmed/29654415 http://dx.doi.org/10.1007/s10549-018-4769-z |
work_keys_str_mv | AT vermasunil healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT oshaughnessyjoyce healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT burrishowarda healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT camponemario healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT albaemilio healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT chandiwanadavid healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT dalalananda healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT sutradharsantosh healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT monacomauricio healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 AT janniwolfgang healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2 |